BR0309025A - Agentes antidiabéticos - Google Patents

Agentes antidiabéticos

Info

Publication number
BR0309025A
BR0309025A BR0309025-6A BR0309025A BR0309025A BR 0309025 A BR0309025 A BR 0309025A BR 0309025 A BR0309025 A BR 0309025A BR 0309025 A BR0309025 A BR 0309025A
Authority
BR
Brazil
Prior art keywords
formula
antidiabetic agents
compounds
preparing compounds
useful
Prior art date
Application number
BR0309025-6A
Other languages
English (en)
Inventor
Stephen Alan Fakhoury
Helen Tsenwhei Lee
Robert Philipp Schaum
Karen Elaine Sexton
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of BR0309025A publication Critical patent/BR0309025A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms

Abstract

"AGENTES ANTIDIABéTICOS". A presente invenção refere-se a compostos de fórmula I: em que X, E,e R<39> têm qualquer um dos valores definidos na especificação, e os seus sais farmaceuticamente aceitáveis, reduzem os níveis de glicose no sangue e são úteis para tratar doenças em mamíferos tais como a Diabetes Mellitus Não-dependente de Insulina. São também descritas formulações farmacêuticas, processos para preparar compostos de fórmula (I) e intermediários úteis para preparar compostos de fórmula I.
BR0309025-6A 2002-04-05 2003-03-25 Agentes antidiabéticos BR0309025A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37045502P 2002-04-05 2002-04-05
PCT/IB2003/001132 WO2003084535A1 (en) 2002-04-05 2003-03-25 Antidiabetic agents

Publications (1)

Publication Number Publication Date
BR0309025A true BR0309025A (pt) 2005-02-01

Family

ID=28792039

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0309025-6A BR0309025A (pt) 2002-04-05 2003-03-25 Agentes antidiabéticos

Country Status (8)

Country Link
US (1) US6716842B2 (pt)
EP (1) EP1492528A1 (pt)
JP (1) JP2005525394A (pt)
AU (1) AU2003215804A1 (pt)
BR (1) BR0309025A (pt)
CA (1) CA2481706A1 (pt)
MX (1) MXPA04009175A (pt)
WO (1) WO2003084535A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7144906B2 (en) * 2000-05-26 2006-12-05 Nippon Shinyaku Co., Ltd. Heterocyclic compounds
AU2003266559B2 (en) * 2002-09-26 2008-01-24 Eisai R&D Management Co., Ltd. Combination drug
ATE420660T1 (de) 2003-08-08 2009-01-15 Amgen Fremont Inc Antikörper gegen parath-hormon (pth) und ihre verwendungen
US7318925B2 (en) * 2003-08-08 2008-01-15 Amgen Fremont, Inc. Methods of use for antibodies against parathyroid hormone
WO2005056536A1 (en) * 2003-12-10 2005-06-23 Ranbaxy Laboratories Limited Antidiabetic agents which exhibit activity against ppar
CA2995617A1 (en) * 2017-11-03 2019-05-03 Universite De Montreal Heterocyclic mitochondrial activity inhibitors and uses thereof

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5089514A (en) 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
HUT70153A (en) 1990-08-23 1995-09-28 Pfizer Hypoglycemic hydroxyurea derivatives
US5232945A (en) 1992-07-20 1993-08-03 Pfizer Inc. 3-aryl-2-hydroxypropionic acid derivatives and analogs as antihypertensives
ZA939516B (en) 1992-12-22 1994-06-06 Smithkline Beecham Corp Endothelin receptor antagonists
GB9311644D0 (en) 1993-06-05 1993-07-21 Smithkline Beecham Plc Novel compounds
US5591862A (en) 1993-06-11 1997-01-07 Takeda Chemical Industries, Ltd. Tetrazole derivatives, their production and use
GB9315148D0 (en) 1993-07-22 1993-09-08 Smithkline Beecham Plc Novel compounds
US5428048A (en) 1993-11-08 1995-06-27 American Home Products Corporation Aryl-N-hydroxyureas as inhibitors of 5-lipoxygenase and anto-arteriosclerotic agents
WO1995018533A1 (en) 1994-01-04 1995-07-13 The Trustees Of The University Of Pennsylvania Methods and compounds affecting adipocyte differentiation and obesity
JPH0832520A (ja) 1994-07-15 1996-02-02 Canon Inc 双方向光空間伝送装置
US5641796A (en) 1994-11-01 1997-06-24 Eli Lilly And Company Oral hypoglycemic agents
US5902726A (en) 1994-12-23 1999-05-11 Glaxo Wellcome Inc. Activators of the nuclear orphan receptor peroxisome proliferator-activated receptor gamma
JPH08325250A (ja) * 1995-05-31 1996-12-10 Sumitomo Metal Ind Ltd 新規置換フェノール誘導体
JPH08325263A (ja) 1995-05-31 1996-12-10 Sumitomo Metal Ind Ltd 新規２−アミノ−３−フェニルプロピオン酸誘導体
US5939442A (en) 1995-06-07 1999-08-17 The Salk Institute For Biological Studies Modulations of peroxisome proliferator activated receptor-γ, and methods for the use thereof
US6413994B1 (en) 1999-02-22 2002-07-02 The Salk Institute For Biological Studies Modulators of peroxisome proliferator activated receptor-gamma, and methods for the use thereof
WO1997010813A1 (en) 1995-09-18 1997-03-27 Ligand Pharmaceuticals Incorporated Ppar gamma antagonists for treating obesity
GB9600464D0 (en) 1996-01-09 1996-03-13 Smithkline Beecham Plc Novel method
GB9604242D0 (en) 1996-02-28 1996-05-01 Glaxo Wellcome Inc Chemical compounds
JP3215048B2 (ja) 1996-04-03 2001-10-02 日本たばこ産業株式会社 プロピオン酸誘導体及びその用途
AU708919B2 (en) 1996-04-04 1999-08-19 Sankyo Company Limited Phenylalkylcarboxylic acid derivatives
IL121203A (en) 1996-07-01 2001-04-30 Lilly Co Eli 1, 2, 3, 4-tetrahydroisoquinidines, process for their preparation and pharmaceutical compositions containing the same for treating hyperglycemia and hyperlipidemia
EP0925063A4 (en) 1996-07-01 2000-12-27 Lilly Co Eli Blood-glucose-lowering and lipid-lowering compounds
AU740444B2 (en) * 1996-08-19 2001-11-01 Japan Tobacco Inc. Propionic acid derivatives and use thereof
WO1998028254A1 (fr) 1996-12-24 1998-07-02 Nippon Chemiphar Co., Ltd. Derives d'acide propionique
EP1067109B1 (en) 1998-03-10 2009-12-09 Ono Pharmaceutical Co., Ltd. Carboxylic acid derivatives and drugs containing the same as the active ingredient
JP2002506033A (ja) 1998-03-10 2002-02-26 スミスクライン・ビーチャム・コーポレイション ビトロネクチン受容体アンタゴニスト
CA2291620C (en) * 1998-03-30 2003-10-07 Japan Tobacco Inc. Production method of isoxazolidinedione compound
WO1999008501A2 (en) 1998-04-23 1999-02-25 Dr. Reddy's Research Foundation New heterocyclic compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them
GB9817118D0 (en) 1998-08-07 1998-10-07 Glaxo Group Ltd Pharmaceutical compounds
JP2002527507A (ja) 1998-10-21 2002-08-27 ノボ ノルディスク アクティーゼルスカブ 新規化合物類、それらの調製及び使用
WO2000035437A2 (en) 1998-12-17 2000-06-22 Mindset Biopharmaceuticals (Usa), Inc. Improving mental performance by increasing brain insulin sensitivity
MXPA01009127A (es) 1999-03-11 2003-07-14 Nuclear Receptor Res Ltd Ligandos novedosos de receptores nucleares, receptores activados por proliferacion de peroxisoma.
JP2000344748A (ja) 1999-03-29 2000-12-12 Welfide Corp ３−芳香族置換プロピオン酸またはアクリル酸化合物
DE60021368T2 (de) 1999-04-19 2006-07-27 Lexicon Pharmaceuticals (New Jersey), Inc. Ppar-(gamma) agonisten zur behandlung von type ii diabetes
EP1171414A1 (en) 1999-04-20 2002-01-16 Novo Nordisk A/S Compounds, their preparation and use
US7348426B1 (en) 1999-04-28 2008-03-25 Dr. Reddy's Laboraties Limited Substituted bicyclic heterocycles, process for their preparation and their use as antiobesity and hypocholesterolemic agents
EE200100556A (et) 1999-04-28 2003-02-17 Aventis Pharma Deutschland Gmbh Diarüülhappe derivaat, seda sisaldav farmatseutiline kompositsioon ja ühendi kasutamine ravimite valmistamiseks
NZ515087A (en) 1999-04-28 2003-11-28 Aventis Pharma Gmbh Tri-aryl acid derivatives as PPAR receptor ligands
GB9914977D0 (en) 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds
GB9919413D0 (en) 1999-08-18 1999-10-20 Zeneca Ltd Chemical compounds
PT1206457E (pt) 1999-08-27 2004-03-31 Lilly Co Eli Derivados de diaril-oxa(tia)zol e seu uso como moduladores dos ppars
DE60008763T2 (de) 1999-09-08 2005-02-10 Glaxo Group Ltd., Greenford Oxazol ppar antagonisten
TW200528436A (en) 1999-09-22 2005-09-01 Bristol Myers Squibb Co Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method
SK6432002A3 (en) 1999-11-10 2003-02-04 Takeda Chemical Industries Ltd 5-Membered N-heterocyclic compounds with hypoglycemic and hypolipidemic activity
JP4316787B2 (ja) 2000-01-11 2009-08-19 壽製薬株式会社 エーテル又はアミド誘導体、その製法並びにそれを含有する糖尿病治療剤、
GB0002667D0 (en) 2000-02-04 2000-03-29 Glaxo Group Ltd medicamesnts
GB0003310D0 (en) 2000-02-15 2000-04-05 Univ Sheffield Bone formation
KR20020081424A (ko) 2000-03-09 2002-10-26 아벤티스 파마 도이칠란트 게엠베하 Ｐｐａｒ 매개인자의 치료학적 용도
US6608038B2 (en) 2000-03-15 2003-08-19 Novartis Ag Methods and compositions for treatment of diabetes and related conditions via gene therapy
MXPA02012708A (es) 2000-06-28 2003-09-22 Tularik Inc Moduladores ppar-gamma de quinolinilo y benzotiazolilo.
AU2001277056B2 (en) 2000-07-25 2005-09-29 Merck & Co., Inc. N-substituted indoles useful in the treatment of diabetes
US6787552B2 (en) 2000-08-11 2004-09-07 Nippon Chemiphar Co., Ltd. PPAR delta activators
AU2001278738A1 (en) 2000-08-16 2002-02-25 Sankyo Company Limited Medicinal compositions for preventing and treating cancer
US7078422B2 (en) 2001-03-23 2006-07-18 Nippon Chemiphar Co., Ltd. Activator for peroxisome proliferator-activated receptor
CZ20033328A3 (cs) * 2001-06-07 2004-06-16 Eli Lilly And Company Modulátory receptorů aktivovaných proliferátory peroxisomů (PPAR)

Also Published As

Publication number Publication date
JP2005525394A (ja) 2005-08-25
MXPA04009175A (es) 2004-12-07
WO2003084535A1 (en) 2003-10-16
US20030225083A1 (en) 2003-12-04
CA2481706A1 (en) 2003-10-16
US6716842B2 (en) 2004-04-06
AU2003215804A1 (en) 2003-10-20
EP1492528A1 (en) 2005-01-05

Similar Documents

Publication Publication Date Title
BR0213539A (pt) Compostos, processo para a preparação de compostos, composições farmacêuticas que compreendem um composto método para o tratamento e/ou profilaxia de enfermidades que estão associadas com dpp iv e utilização desses compostos
BRPI0411713B8 (pt) compostos, processo para a sua manufatura, composições farmacêuticas que compreendem os mesmos, método para tratamento e/ou profilaxia de enfermidades que estão associadas com dpp-iv e sua utilização
BR0210711A (pt) Uso de um composto, composição farmacêutica, composto, e, processo para a preparação de um composto
BR0307576A (pt) Compostos; processo para a fabricação de compostos; composições farmacêuticas; método para o tratamento e/ou profilaxia de doenças associadas com o dpp iv; e uso de compostos
BR0307665A (pt) Compostos, processo para a sua manufatura, composições farmacêuticas que compreendem os mesmos, método para o tratamento e/ou profilaxia de enfermidades associadas com dpp iv e utilização dos compostos
BR0010080A (pt) Inibidores de renina
PT1213296E (pt) Derivados de glucopiranosiloxipirazole composicoes medicas que os contem e intermediarios na sua producao
BRPI0411509A (pt) compostos, processo para a sua manufatura, composições farmacêuticas que compreendem os mesmos, método para tratamento e/ou profilaxia de enfermidades que estão associadas com dpp-iv e sua utilização
BR0215396A (pt) Compostos, processo para a manufatura de compostos, composições farmacêuticas, método para o tratamento e/ou profilaxia de enfermidades que estão associadas com &#34;dpp-iv&#34; e utilização dos compostos
BR0317435A (pt) Derivados de pirimidina para o tratamento do crescimento celular anormal
BR0312513A (pt) Derivados de glicosìdeo de tiofeno, processos para a produção dos mesmos, medicamentos que contêm esses compostos e uso dos mesmos
BRPI0415613A (pt) novos compostos de diazaspiroalcanos e seu uso no tratamento de doenças mediadas por ccr8
BR0308212A (pt) Composto, composição farmacêutica, e, uso de um composto
BRPI0410760A (pt) compostos, processo para fabricação dos mesmos, composições farmacêuticas e uso deste compostos
BR0214986A (pt) S-enanciÈmero de um composto, composto, formulação farmacêutica, método de tratamento ou prevenção de distúrbios de lipìdeo, uso de um composto, método de tratamento ou prevenção de diabetes tipo 2, processo para a preparação de um composto, e, composição farmacêutica
BR9911482A (pt) Composto, composição farmacêutica, uso do composto, e, processos para o tratamento ou profilaxia de doenças inflamatórias, e para a preparação de um composto
BRPI0410477A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, método para a profilaxia ou tratamento de uma condição quiral em um mamìfero, formulação farmacêutica, combinação, uso de um composto, e, processo para preparar um composto
BRPI0518898A2 (pt) composto, processo para sua preparaÇço, composiÇço farmacÊutica, mÉtodo para tratamento e uso do composto
BR0309012A (pt) Uso de um composto, formulação farmacêutica, composto, composição farmacêutica, e, processo para a preparação de um composto
EP1400529A4 (en) GLUCOPYRANOSYLOXYPYRAZOLE DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND MEDICINAL AND INTERMEDIARY USE THEREOF
ATE427926T1 (de) Cycloalkylaminderivate
BRPI0508724A (pt) derivados do fenilaminoetanol como agonistas do receptor beta2
BR0315047A (pt) Composto, composição fermacêutica que compreende o mesmo, processo para a preparação da composição farmacêutica, utilização dos compostos, método de tratamento e processo para a preparação do composto
BRPI0511874A (pt) derivados da pirrolopiridina
BRPI0411891A (pt) pirazol[3,4-b]piridin-6-onas como inibidores de gsk-3

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A,6A E 7A ANUIDADES

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2051 DE 27/04/2010.